Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Intellipharmaceutics International Inc (IPCIF)

Intellipharmaceutics International Inc (IPCIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intellipharmaceutics International Inc 30 WORCESTER ROAD TORONTO A6 M9W 5X2 CAN

www.intellipharmaceutics.com P: 416-798-3001

Description:

Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada.

Key Statistics

Overview:

Market Capitalization, $K 1,986
Enterprise Value, $K 3,706
Shares Outstanding, K 33,093
Annual Sales, $ 70 K
Annual Net Income, $ -2,890 K
Last Quarter Sales, $ 70 K
Last Quarter Net Income, $ -1,890 K
EBIT, $ -2,410 K
EBITDA, $ -2,200 K
60-Month Beta 1.16
% of Insider Shareholders 1.76%
% of Institutional Shareholders 0.00%
Float, K 32,511
% Float 98.24%
Short Volume Ratio 1.00

Growth:

1-Year Return 200.00%
3-Year Return -74.14%
5-Year Return -67.05%
5-Year Revenue Growth -98.73%
5-Year Earnings Growth 96.90%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.06 on 10/16/23
Latest Earnings Date 06/04/24
Earnings Per Share ttm -0.16
EPS Growth vs. Prev Year -500.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

IPCIF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -4,128.57%
Debt/Equity -0.14
Price/Sales 2.36
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.39
Interest Coverage -8.97
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar